Glaxo, Xenoport’s drug gets FDA nod for new use

A GlaxoSmithKline logo is seen outside one of its buildings in west London(Reuters) – Drugmaker XenoPort Inc and its partner GlaxoSmithKline Plc said the U.S. health regulator approved their drug to treat shingles related nerve pain that may cause disability in some people. XenoPort will get a milestone payment of $ 10 million from Glaxo following first sales of the drug, Horizant, to treat post-herpetic neuralgia (PHN) in adults. Post-herpetic neuralgia follows the healing of an outbreak of herpes zoster, commonly known as shingles. Around a million people in the United States develop shingles each year and about 10 percent of those develop PHN. …



Sexual Health News Headlines – Yahoo! News